These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12589849)

  • 21. The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus load.
    Kawamura Y; Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kobayashi M; Kumada H
    Intern Med; 2008; 47(5):355-60. PubMed ID: 18310963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial.
    Alaimo G; Di Marco V; Ferraro D; Di Stefano R; Porrovecchio S; D'Angelo F; Calvaruso V; Craxì A; Almasio PL
    World J Gastroenterol; 2006 Nov; 12(42):6861-4. PubMed ID: 17106937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
    Pár A; Tornai I; Szalay F
    Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of hepatitis B vaccination and interferon-alpha-2b combination therapy versus interferon-alpha-2b monotherapy in children with chronic hepatitis B.
    Helvaci M; Kizilgunesler A; Kasirga E; Ozbal E; Kuzu M; Sozen G
    J Gastroenterol Hepatol; 2004 Jul; 19(7):785-91. PubMed ID: 15209626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of hepatitis B virus associated glomerulonephritis with recombinant human alpha interferon.
    Chung DR; Yang WS; Kim SB; Yu E; Chung YH; Lee Y; Park JS
    Am J Nephrol; 1997; 17(2):112-7. PubMed ID: 9096440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study.
    Liu CJ; Lai MY; Chao YC; Liao LY; Yang SS; Hsiao TJ; Hsieh TY; Lin CL; Hu JT; Chen CL; Chen PJ; Kao JH; Chen DS
    Hepatology; 2006 Apr; 43(4):742-9. PubMed ID: 16557544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: outcome after resumption of therapy.
    Wong VK; Cheong-Lee C; Ford JA; Yoshida EM
    World J Gastroenterol; 2005 Sep; 11(34):5392-3. PubMed ID: 16149154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of human recombinant erythropoietin plus IFN-alpha in patients affected by chronic hepatitis C.
    Di Fazio I; Motta M; Musumeci S; Neri S; Pistone G; Malaguarnera M
    J Interferon Cytokine Res; 2004 Oct; 24(10):594-9. PubMed ID: 15626156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Psychiatric adverse effects induced by recombinant interferon alfa in patients with chronic hepatitis C].
    Nesić Z; Delić D; Prostran M; Stojanović R; Vucković S; Todorović Z
    Med Pregl; 2004; 57(5-6):219-26. PubMed ID: 15503789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations.
    Shi M; Wang RS; Zhang H; Zhu YF; Han B; Zhang Y; Jin LJ; Yang ZJ; Xu YP
    J Antimicrob Chemother; 2006 Nov; 58(5):1031-5. PubMed ID: 16987866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP).
    Janssen HL; Gerken G; Carreño V; Marcellin P; Naoumov NV; Craxi A; Ring-Larsen H; Kitis G; van Hattum J; de Vries RA; Michielsen PP; ten Kate FJ; Hop WC; Heijtink RA; Honkoop P; Schalm SW
    Hepatology; 1999 Jul; 30(1):238-43. PubMed ID: 10385662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin.
    Formann E; Stauber R; Denk DM; Jessner W; Zollner G; Munda-Steindl P; Gangl A; Ferenci P
    Am J Gastroenterol; 2004 May; 99(5):873-7. PubMed ID: 15128353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.
    Lampertico P; Del Ninno E; Viganò M; Romeo R; Donato MF; Sablon E; Morabito A; Colombo M
    Hepatology; 2003 Apr; 37(4):756-63. PubMed ID: 12668967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy.
    Akyuz F; Kaymakoglu S; Demir K; Aksoy N; Karaca C; Danalioglu A; Onel D; Badur S; Besisik F; Cakaloglu Y; Okten A
    Acta Gastroenterol Belg; 2007; 70(1):20-4. PubMed ID: 17619534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter study.
    Dikici B; Ozgenc F; Kalayci AG; Targan S; Ozkan T; Selimoglu A; Doganci T; Kansu A; Tosun S; Arslan N; Kasirga E; Bosnak M; Haspolat K; Buyukgebiz B; Aydogdu S; Girgin N; Yagci RV
    J Gastroenterol Hepatol; 2004 Feb; 19(2):127-33. PubMed ID: 14731120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial.
    Karabay O; Tamer A; Tahtaci M; Vardi S; Celebi H
    J Microbiol Immunol Infect; 2005 Aug; 38(4):262-6. PubMed ID: 16118673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of standard and high dosage recombinant interferon alpha 2b for treatment of children with chronic hepatitis B infection.
    Gürakan F; Koçak N; Ozen H; Yüce A
    Pediatr Infect Dis J; 2000 Jan; 19(1):52-6. PubMed ID: 10643851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.